The next stage is a human trial, but this must be approved
Scientists from the United States published the first results of preclinical trials of a coronavirus vaccine in the journal EBioMedicine. During experiments with laboratory mice, it was found that the potential vaccine, when ingested, contributes to the production of specific antibodies, which should be sufficient to neutralize COVID-19.
In their work, the scientists relied on the experience of countering SARS and MERS viruses. It is clarified that both of these pathogens are close relatives of COVID-19, and one of their shell proteins, S-protein, is important for the formation of the immune response, the scientists explained.
Experiments were conducted on laboratory mice, it was found that the developed vaccine, once in the body, contributes to the production of SARS-CoV-2-specific antibodies, which should be sufficient to neutralize the virus.
The next stage is a human trial,but this must be approved.